Current Report Filing (8-k)
20 April 2016 - 8:54PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 20, 2016
Bio-Matrix
Scientific Group, Inc.
(Exact
Name of Company as Specified in Charter)
Commission
File Number: 0-32201
|
|
Delaware
|
33-0824714
|
(State
or Other Jurisdiction of
Incorporation)
|
(IRS
Employer Identification
Number)
|
4700
Spring Street, St 304
La
Mesa California, 91942
(Address
of Principal Executive Offices, Zip Code)
Company’s
telephone number, including area code:
(619)
702-1404
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events
On
April 20, 2016 Regen Biopharma, Inc.’s Series A Preferred stock commenced publicly trading on the OTC Pink market. The OTC
Pink market is operated by OTC Markets Group. As of March 31, 2016 Bio Matrix Scientific Group, Inc. owns 2,907,666 shares of
Regen Biopharma, Inc.’s Series A Preferred stock.
Regen
Biopharma, Inc.’s Series A Preferred stock trades over the OTC Pink market under the symbol RGBPP.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIO
MATRIX SCIENTIFIC GROUP, INC.
|
|
|
Dated: April 20, 2016
|
By:
/s/
David Koos
|
|
David Koos
|
|
Chief Executive Officer
|